Biodesix: a New Way to Inform Cancer Treatment Selection (Rocky Radar)

 

“One data point doesn’t tell you very much in most cases,” comments David Brunel, CEO of Biodesix, a medical diagnostics company based in Broomfield, Colorado. This principle guides Biodesix’s approach to developing diagnostics which aim to identify a patient’s expected response to a particular therapeutic.

This story is no longer available from Rocky Radar.

 

For Customer Support, call: (866) 432-5930

 

Topics: blood-based cancer test, cancer diagnostics, personalized medicine, molecular diagnostic, Non-Small Cell Lung Cancer, oncology, cancer treatment, In the News, rocky radar